Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "IOL-Chemicals-and-Pharmaceuticals"

33 News Found

Diversification by pharma companies critical to repositioning supply chain
News | March 02, 2022

Diversification by pharma companies critical to repositioning supply chain

Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel

IOL receives Korean FDA approval
Drug Approval | October 14, 2021

IOL receives Korean FDA approval

The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead

IOL Chemicals and Pharma commissions Unit-10 for Rs 28.69 crores
News | August 16, 2021

IOL Chemicals and Pharma commissions Unit-10 for Rs 28.69 crores

'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22

Latest Stories

NVIDIA partners with Novo Nordisk and DCAI to advance drug discovery

Bristol Myers Squibb announces positive results from Phase 3 Poetyk PsA-1 and PsA-2 trials of deucravacitinib in psoriatic arthritis

FDA approves AbbVie’s mavyret as first and only treatment for acute hepatitis C

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging